- TV Footage
- Integrated Annual Reports
- Quarterly Statements
- Newsletter Overview
- Social Media
- Media Contact
Monheim, Germany, October 16, 2019 – Bayer Animal Health GmbH and VLPbio – The Vaccines Company S.L. have signed a global collaboration agreement to discover and develop a new generation of immunotherapeutic solutions that address the high demand for innovative treatment options in the field of veterinary medicine.
Bayer Animal Health and VLPbio have agreed to jointly discover and develop immunotherapeutics for animals based on VLPbio´s technology, which is designed to induce specific immune responses against target animal diseases. The two companies will share knowledge about animal diseases and develop strategic approaches towards customer-focused treatment alternatives. The collaboration aims to create tools to shape the future of animal health and to develop new products for prevention and treatment of animal diseases, thereby improving animal well-being.
Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said: “This partnership will allow us to intensify our focus on immunotherapeutics. We are proud to collaborate with one of the most innovative start-ups in the industry and strongly believe that this collaboration will enhance our innovation capabilities.”
VLPbio CEO Pablo Gutiérrez commented: “Our commitment to this collaboration is based on three competitive advantages of our company: the innovative potential of our technology, the experience and capacity of our team as well as a solid strategic plan. This position is also being recognized in the industry. VLPbio was one of 12 innovation showcase finalists to pitch for investment in their products and technologies in the field of Health at the Animal Health Investment Forum Europe 2019.”
VLPbio is a technological company based out of Spain that develops novel vaccines and other immunotherapies against high-impact diseases in the veterinary field based on chimeric virus-like particles (Ch-VLPs). VLPbio uses a proprietary technology which acts as an antigens-display platform for a specific target and activates an immune response. The company has a strong and diversified portfolio of products under development targeting a global market of more than 1 billion euros. For more information, go to https://vlpbio.com/.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center